Brief: Virios Therapeutics Says Co Continues To Actively Explore Opportunities For Three Initiatives
03/01/2024 12:43
Jan 3 (Reuters) - Virios Therapeutics Inc VIRI.O :
* VIRIOS THERAPEUTICS- CONTINUE TO ACTIVELY EXPLORE
OPPORTUNITIES
FOR IMC-1 FOR A PHASE 3 FIBROMYALGIA PROGRAM,IMC-2 FOR A PHASE 2
LONG-COVID PROGRAM
Further company coverage: VIRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dogwood Therapeutics
See all newsDogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dogwood Therapeutics Q2 net loss widens on higher costs, impairment charge
Brief: Dogwood Therapeutics Q2 EPS USD -0.34
Dogwood Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Dogwood Therapeutics Announces Commencement Of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2B Long Term Extension Study